Go Ad-Free
logoThe People's Perspective on Medicine

Biotech Offers New Weapon against C Difficile Diarrhea

One of the big challenges for hospitals is to keep patients from picking up a nasty infection while they are being treated for something else. One of the most worrisome is Clostridium difficile, or C diff for short. This bug causes severe diarrhea that may become life threatening.
Antibiotic therapy is not always successful. That’s why a new approach to treating C diff is generating a great deal of interest. Researchers report that monoclonal antibodies to the toxins produced by these bacteria can be effective in preventing recurrences. Reducing the spread of C diff in hospitals with good infection control practices and utilizing new immunotherapy may help doctors defeat a dangerous bug.
[New England Journal of Medicine, Jan. 21, 2010]

Rate this article
star-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-emptystar-fullstar-empty
0- 0 ratings
About the Author
Terry Graedon, PhD, is a medical anthropologist and co-host of The People’s Pharmacy radio show, co-author of The People’s Pharmacy syndicated newspaper columns and numerous books, and co-founder of The People’s Pharmacy website. Terry taught in the Duke University School of Nursing and was an adjunct assistant professor in the Department of Anthropology. She is a Fellow of the Society of Applied Anthropology. Terry is one of the country's leading authorities on the science behind folk remedies..
Tired of the ads on our website?

Now you can browse our website completely ad-free for just $5 / month. Stay up to date on breaking health news and support our work without the distraction of advertisements.

Browse our website ad-free
Join over 150,000 Subscribers at The People's Pharmacy

We're empowering you to make wise decisions about your own health, by providing you with essential health information about both medical and alternative treatment options.